ReviewFrontiers in cell and developmental biology2022
Advances and development of prostate cancer, treatment, and strategies: A systemic review.
Review in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Effect of Prostate Cancer Education on Saudi Men: Knowledge, Beliefs, and Screening Intentions.Asian Pacific journal of cancer prevention : APJCP · 2024Trial
- Diagnosis of Prostate Cancer: A Comparative Evaluation of Biological Techniques.Diseases (Basel, Switzerland) · 2026Review
- Incidence of High-Risk Prostate Cancer in Korea: Insights From Real-World Data Between 2010 and 2020.Journal of Korean medical science · 2026Article
- Age-Related Epigenetic Drift Shapes Coordinated microRNA Promoter Methylation and Expression in Prostate Cancer.Epigenomes · 2026Article
- Preclinical Evaluation Study ofChemical & biomedical imaging · 2026Article
- Synthesis, radiolabeling, and biodistribution evaluation of novel hyperbranched polyglycerols-based radiotracers for targeting PSMA in prostate cancer.Iranian journal of basic medical sciences · 2026Article
- Reduced immunogenicity of MYC amplified, metastatic prostate cancer.Oncoscience · 2026Article
- Development and In Vitro Evaluation of [International journal of molecular sciences · 2025Article
- Deep learning assisted identification of SCUBE2 and SLC16 A5 combination in RNA-sequencing data as a novel specific potential diagnostic biomarker in prostate cancer.Medical & biological engineering & computing · 2025Article
- Endothelial-Mesenchymal Transition in Tumor Microenvironment Promotes Neuroendocrine Differentiation of Prostate Cancer.Cancer science · 2025Article
- Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase.Antibody therapeutics · 2025Article
- Deep Learning Techniques for Prostate Cancer Analysis and Detection: Survey of the State of the Art.Journal of imaging · 2025Review
- Unveiling the anticancer potential of Curcuma amada rhizome extract against prostate cancer through computational and experimental approaches.Scientific reports · 2025Article
- Global trends in testicular and prostate cancer among adolescents and young adult males aged 15-49 years, 1990-2021: insights from the GBD study.Scientific reports · 2025Article
- CEG-0598, a novel dual inhibitor of EGFR and C5aR demonstrates in vitro anticancer and antimetastatic activity in prostate cancer cells.Discover oncology · 2025Article
- Using XBGoost, an interpretable machine learning model, for diagnosing prostate cancer in patients with PSA < 20 ng/ml based on the PSAMR indicator.Scientific reports · 2025Article
- The global, regional, and national prostate cancer burden and trends from 1990 to 2021, results from the global burden of disease study 2021.Frontiers in public health · 2025Article
- Association of visceral obesity indicators with prostate cancer: a cross-sectional study from Xinjiang.Frontiers in oncology · 2025Article
- Clinicopathologic features and prognosis of incidental prostate cancer after radical cysto-prostatectomy: a comparative study between China and the West.Translational andrology and urology · 2024Article
- Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatform for interleukin-30 genome editing.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common type of cancer in the present-day world affecting modern-day men after lung cancer is prostate cancer. Prostate cancer remains on the list of top three cancer types claiming the highest number of male lives. An estimated 1.4 million new cases were reported worldwide in 2020. The incidence of prostate cancer is found predominantly in the regions having a high human development index. Despite the fact that considerable success has been achieved in the treatment and management of prostate cancer, it remains a challenge for scientists and clinicians to curve the speedy advancement of the said cancer type. The most common risk factor of prostate cancer is age; men tend to become more vulnerable to prostate cancer as they grow older. Commonly men in the age group of 66 years and above are the most vulnerable population to develop prostate cancer. The gulf countries are not far behind when it came to accounting for the number of individuals falling prey to the deadly cancer type in recent times. There has been a consistent increase in the incidence of prostate cancer in the gulf countries in the past decade. The present review aims at discussing the development, diagnostics
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.